Evangelia Vemmou (@evivemmou) header
Evangelia Vemmou (@evivemmou) profile picture

second-year @UCSFcardiology fellow | past:@YaleIMed @mhif_heart @SNForg @uoaofficial | views my own

New Haven, CT
Joined May 2011
Photo by Evangelia Vemmou (@evivemmou)Photo by Evangelia Vemmou (@evivemmou)Photo by Evangelia Vemmou (@evivemmou)Photo by Evangelia Vemmou (@evivemmou)Photo by Evangelia Vemmou (@evivemmou)Photo by Evangelia Vemmou (@evivemmou)Photo by Evangelia Vemmou (@evivemmou)Photo by Evangelia Vemmou (@evivemmou)Photo by Evangelia Vemmou (@evivemmou)Photo by Evangelia Vemmou (@evivemmou)
Evangelia Vemmou retweeted
Here are my initial thoughts on Lp(a)HORIZON. This is targeted to the people to whom it matters the most, my wonderful PATIENTS over the years in my Lp(a) Clinic. I have done my best to keep you healthy, and for the most part it worked. And I think this is reflected in the results of the Lp(a)HORIZON trial. This is also for those with elevated Lp(a) that been carrying significant anxiety and concern over their elevated levels. 1- Big picture: I do not see Lp(a)HORIZON as a failure, like many Monday morning quarterbacks out there who claim to have known the results all along after all. I see it as a MAJOR SUCCESS for our patients. 2- Why? Because we learned that there may be an alternative to reduce Lp(a) mediated risk: which is to: a) keep LDL-C below 65 or lower; b) keep blood pressure at 120 or lower; c) control all other risk factors as best as possible; d) take your medicines that have proven efficacy regularly. 3- I have called Lp(a)HORIZON testing the “Lp(a) Hypothesis”. Which means we did not know if lowering Lp(a) would benefit patients. If we knew Novartis would not have spent >1 billion dollars to do the trial and the FDA would have approved the drug simply on Lp(a) lowering. 4- Why did we not see a benefit in specifically lowering Lp(a) in Lp(a)HORIZON? I think we need to go back to “first principles” in how Lp(a) causes atherothrombosis. It is a minor contributor to atherosclerosis. It is a major contributor to inflammation, via OxPL. It is also anti-fibrinolytic- NOT pro-thrombotic. That means it contributes to vulnerable plaques but not to “plaque burden”. And it contributes to a blood clots enlarging and occluding blood vessels if clots are already made, but not in making blood clots per se. 5- So if one is intensively treated to remove the nidus for vulnerable plaques and clot formation, like the patients in HORIZON (and in the ongoing trials), then Lp(a) may become quiescent. 6- In my Lp(a) Clinic, this is my summary of how I treat my patients: 75% on statin, 50% of ezetimibe and 50% (!!) on PCSK9i, along with judicious use of aspirin in primary prevention and universal use in secondary prevention. This double/triple/quadruple combo is highly effective. If I see no coronary calcium or evidence of atherosclerosis, I am not aggressive with therapy if otherwise not indicated for another reason. 7- That being said, 1 out of 8 people still had an event in Lp(a) HORIZON. So, we need to figure out why beyond classical lipids and blood pressure. I am already thinking 10 yrs ahead and will have new concepts for this issue in near future. 8- I do not think the Lp(a)HORIZON results apply to Aortic Stenosis, as this is not affected by LDL-C or for the most part aspirin, but is more @OxPL_apoB driven in people with high Lp(a). I think we owe a huge debt of gratitude for the Lp(a)HORIZON trial, to @novartis and to @ionispharma for leading the Lp(a) field. And to circle back to people with elevated Lp(a): Lp(a)HORIZON has now armed us with actionable (and inexpensive) knowledge to help people with elevated Lp(a). Take a big breath and sigh of relief, Lp(a) risk can be managed. Treat it like you do other risk factors and your prognosis will be good, like many of my Lp(a) Clinic patients. We do need to do more work to figure out, among those with elevated Lp(a), who are highest risk, and target those in future studies, I will provide more scientific comments at a later time and will be publishing my thoughts in a journal in the future. With all that said, we still don't know the physiological function of Lp(a), if any, and why >99.99% have some circulating Lp(a) and why 1 in 5 have very high levels. Knowing this may give us the ultimate answer on Lp(a) and it role not only in CV disease but also in life and longevity. Along with my collaborators, we will have something on this also in near future. Thank you all for following Lp(a)'s journey in these pages. The story is actually in the middle not at the end...a few more chapters are in the works.
52
121
18
544
62,724
Evangelia Vemmou retweeted
🌍🫀 The growing global burden of degenerative mitral valve disease! Are we doing enough to improve access to timely mitral valve care? 📊 New data presented by Dr. Juan F. Granada at #TCT2026, spanning 204 countries: 🔹 16.1M prevalent cases in 2023 (↑126% since 1990) 🔹 39,800 deaths (↑75%) 🔹 1.02M disability-adjusted life years (↑66%) 🎯 Despite a 32% decline in age-standardized mortality, absolute deaths continue to rise, with striking disparities between high- and low-SDI settings. 💡 Timely diagnosis and equitable access to mitral valve care remain critical. #MitralRegurgitation #StructuralHeart #CardioX #GBD @ladyheart_md @iamritu @crfheart @TCTMD @NEJM @Shikha_Cardio @purviparwani
1
8
11
965
Evangelia Vemmou retweeted
A splash of colour (in every sense). In the age of Claude, ChatGPT, NotebookLM, and who knows how many others, seeing the Lp(a)HORIZON slides bring back an old classic—the electric-blue background with white and yellow text, straight out of the 2000s—is truly heartwarming.
11
11
1
164
9,966
Final round of selfies from #TCT2026 My take home from this year’s @TCTConference @crfheart 1) LBCT were very strong & highly relevant to practice even if “negative” & ranged from pharma, structural & coronary trials 2) The central illustrations that were displayed in the main arena for each LBCT were EXCELLENT..would suggest sharing those on #SoMe rather than the other AI generated ones 3) Best Practice sessions were intimate & lent themselves to nuanced conversations with key experts.. pls keep them next year 4) TCT AI Lab & Innovation theater were a welcome novel addition to the program & very well planned (topic/faculty) 5) Live cases were diverse ✅.. perhaps some planning & coordination with the whiteboard expert & the panel would optimize the educational value 6) Attendance was remarkable & despite a huge convention center, we were still able to network @djc795 @AdamGreenbaumMD @realarainmd @KAlaswadMD @ColletCarlos et al 7) As much as I love California😎, it’s far … See you all 2027
1
8
59
3,351
Evangelia Vemmou retweeted
What were the biggest takeaways from Day 3️⃣ of #TCT2026? Drs. @rallamee, John A. Spertus and Sanket Dhruva share their perspectives on the latest clinical trial findings, including PROGRESS and CLASP II TR. 📹 Watch the full video 👉 bit.ly/4z198YO #CardioX
10
1
39
4,447
Evangelia Vemmou retweeted
Recruiting for cardiology research fellow - come find us tomorrow at TCT if interested - apply here: workforcenow.adp.com/mascsr/…
Day 3 at #TCT2026! 🌴 Here's the CCAD lineup (Nov 2) including CTO PCI, drug-coated balloons, coronary physiology, CCTA-guided stent sizing, and live case discussions. Come join us! 👇 @TCTConference @esbrilakis @yadersandoval @Bavana_Rangan #CTOPCI #InterventionalCardiology
3
12
74
6,455
Evangelia Vemmou retweeted
PROGRESS presented at #TCT2026: Among patients with moderate aortic stenosis and at-risk features, a TAVR strategy was superior to clinical surveillance in reducing the 2-year incidence of death or HF events. The primary endpoint was largely driven by HF hospitalizations, in the context of an unavoidable open-label design. A highly selected population, enriched for risk factors. Medical therapy may also have been suboptimal relative to current standards or evolving evidence. Finally, does intervening earlier in the natural history of the disease mean starting the durability clock sooner than necessary? nejm.org/doi/full/10.1056/NE…
9
32
1
144
23,860
Evangelia Vemmou retweeted
Presented at #TCT2026: In a randomized trial, CCTA-guided PCI with structured preprocedural planning and intraprocedural guidance was noninferior to intravascular ultrasound–guided PCI with respect to target-vessel failure at 12 months. Full P4 trial results: nej.md/48jfVly @crfheart
4
86
18
248
36,322
Evangelia Vemmou retweeted
The Golden State Valkyries are WNBA champions 🏆 In just their second year of existence, the Valkyries have reached the mountaintop.
22
111
5
597
82,473
Evangelia Vemmou retweeted
AI is transforming cardiovascular medicine—and how we learn, teach, and understand. Excited to share The Physiology Lab, a new, open-access interactive tool to explore coronary physiology. 💻 systole.live/lab.html This is just the beginning. 🫀 The U.S. Physiology Course | Feb 1–2, 2027 | Charlotte, NC: event.fourwaves.com/systole-… @esbrilakis @ColletCarlos @wfearonmd @DrArgyle @claireraph @BernardBruyne @JEscaned @MortonKern @SYSTOLE_live @realarainmd #TCT2026
7
69
2
287
17,744
Evangelia Vemmou retweeted
This year, TCT is stopping in San Diego (and I’ll have to take three flights to get there), and the late-breaking lineup is quite interesting. Here are my favourites, both journalistically and from an interventional cardiology perspective: 1/ P4, a trial of CCTA-guided vs IVUS-guided PCI. We published the design paper in EuroIntervention. Check it out: eurointervention.pcronline.c… 2/ TRANSFORM II, or DCB strategy vs DES, Act III. With REC-CAGEFREE I coming out negative and SELUTION DeNovo being so-so, we really needed a tiebreaker. And here it is. 3/ HD-PCI, a randomized trial of higher vs lower-dose heparin for PCI. I like trials that answer practical, “in or out” questions. I also have to discuss this one right after the presentation, so I’m studying it carefully. 4/ PROGRESS: TAVR or clinical surveillance for moderate aortic stenosis. I still haven’t quite figured out the ambition and magnitude of these TAVR trials in moderate AS. The first one, TAVR UNLOAD, didn’t leave much of a mark. We don’t know when EXPAND TAVR II will be presented, but I suspect it’ll be soon. And then there’s PROGRESS, the largest of them all in terms of patient numbers. By the way, ClinicalTrials.gov says follow-up will end in 2037. As we say back home, campa cavallo. 5/ SIMPLAAFY, antithrombotic monotherapy after left atrial appendage occlusion. I like this trial if only for its name, and I can’t wait to hear how people pronounce it. More importantly, it could give DAPT a serious shove out the door, since it seems to be the main burden holding back LAAO at the moment. 6/ PIONEER IV, angiography-derived FFR vs usual care for lesion selection and optimization in all-comers PCI. Another QFR trial occupying an intermediate position on the physiology spectrum between FAVOR III Europe and FAVOR III China. 7/ VERONICA, where researchers are trying to demonstrate the usefulness of platelet-function testing to identify patients with excessive platelet inhibition (usually, it’s the opposite) and see whether a de-escalation strategy could reduce the combined risk of ischemic and bleeding events.
5
31
2
104
9,537
Evangelia Vemmou retweeted
We have known about #WPW and accessory pathways as a common cause of SVT for >100 years and have effective procedures to address them, but we still have NO IDEA why some patients are born with these extra slivers of muscle that electrically connect atria to ventricles. Medicinal use of lithium in pregnant women leads to heightened risk of a particular form of congenital heart disease associated with these pathways. Might variable levels of lithium in drinking water affect the chance a growing fetus will be born with such a pathway? @jclinicalinvest @UCSF @UCSFHospitals @stopafib @DrDave01 @KnowYourPulse JCI - Elevated lithium levels in drinking water are associated with higher prevalence of Wolff-Parkinson-White diagnoses jci.org/articles/view/205020
2
24
1
76
13,893
Evangelia Vemmou retweeted
These next few years are going to be full of bright cardiology fellows and early attendings just pumping out great teaching tools. Literally in the last 48 hours I've seen a coronary visualizer (learncoronary.com), an echo simulator (intro2echo.com), now a PVC localizer.
PVC localization has been one of the harder things to learn and teach as a cardiology fellow interested in EP. So I built learnpvcs.com to help connect the 12-lead ECG with 3D cardiac anatomy. You can explore different PVC origins, rotate and look inside the heart, and work through practice cases. It's an early educational prototype, and I'd love feedback from fellows, electrophysiologists, and educators. Which PVC origin do you find hardest to localize? #CardioTwitter #EPeeps #MedEd @OpenAI @WvuCvFellows @wvudeptofmed
4
41
196
20,437
Evangelia Vemmou retweeted
I created LearnCoronary (learncoronary.com), an interactive tool designed to help general cardiology fellows and other early-career learners better understand coronary angiography and the spatial relationships between different angiographic views. #cardiotwitter @OpenAI
60
437
23
2,044
111,433
Evangelia Vemmou retweeted
Not sure how it works where you are, but many PCI reports I see end with a somewhat self-absolving statement about "excellent procedural success", based largely on the operator’s visual estimate (i.e., the judgment is in the eye of the beholder). Well, this study shows that when success is defined using standardized criteria and assessed by a core lab, things look quite different and success rates drop substantially. ORIGINAL RESEARCH: eurointervention.pcronline.c… EDITORIAL: eurointervention.pcronline.c…
11
42
5
130
15,462
Evangelia Vemmou retweeted
📣Applications open for 2027-2028 CHIP-CTO Fellowship @MHIF_Heart . @esbrilakis @yadersandoval @CCAD_MHIF Apply: allina.wd5.myworkdayjobs.com…
📢 Applications are open for the 2027-2028 CHIP/CTO Fellowship in Minneapolis! Advanced training in complex coronary interventions & CTO PCI. 🔎 Learn more: mplsheart.org/center-coronar… 📝 Apply: allina.wd5.myworkdayjobs.com… @esbrilakis @yadersandoval @Bavana_Rangan #CHIP #CTO #PCI
2
9
422
Congratulations to @mderdem3 on her publication this week in @MyJSCAI examining our experiences at @HMethodistCV in patients with severe #Mitralregurgitation At @MethodistHosp we found no sex differences in time from diagnosis to referral to our structural team, with the delay time shortening over time #valveteam @NadeenFaza @SLittleMD @WilliamZoghbi @HMHCardioFellow @AlanLumsdenMD 🔗 jscai.org/article/S2772-9303…
🫀Excited to share our work, now published in @JSCAI! ❓Do women and men with severe MR experience different delays in reaching the structural heart team? ➡️We looked at referral timing among patients undergoing M-TEER @DeBakeyCVedu 🧵 sciencedirect.com/science/ar…
1
8
28
4,517
Evangelia Vemmou retweeted
P4 is the first large RCT investigating the value of CT-guided PCI We will present the results at the @TCTMD Late Breaking Clinical Trial session @crfheart @GEHealthCare @Heartflow
🆕🔥🔥🔥The P4 randomised clinical trial evaluates whether a comprehensive CCTA-guided PCI strategy is non-inferior to IVUS-guided PCI for 12-month target vessel failure. The CCTA strategy integrates anatomical and plaque assessment, FFRCT, virtual PCI planning, and intraprocedural CT-fluoroscopy co-registration. 🔗eurointervention.pcronline.c… @bouissetfred @belmontemarta1 @ziadalinyc @SimoneBiscaglia @engstr_thomas @RajMakkarMD @TheLADoctor @DrPeterOKane @divaka_perera @gpontone1 @yadersandoval @gmincione96 @GGStefanini @Eric_Van_Belle @DMunhoz @KoshiroSakai_MD @sbrugaletta @AIhdayhid @JonathonLeipsic @BernardBruyne @Ganeev @DAndreiniMD @ColletCarlos
1
29
76
6,531
Evangelia Vemmou retweeted
Just published in #JACCINT: SCAI/ASE/HRS/SIR/SVS Expert Consensus Statement, led by @RizikMd, advises training, monitoring, and calls for mandatory implementation of enhanced radiation protection devices to meet #ALARA standards. Read the full text here: jacc.org/doi/10.1016/j.jcin.…
1
24
2
53
16,876